Spherix Global Insights finds that pipeline therapies for non-alcoholic fatty liver disease / non-alcoholic steatohepatitis will need to strike a balance between reducing liver fat, improving fibrosis, and ensuring patient safety as they seek FDA approval

EXTON, Pa., May 5, 2021 / PRNewswire / – Spherix recently interviewed 99 US gastroenterologists and 23 hepatologists and conducted ten qualitative interviews to assess the current and future management of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The combination of qualitative and quantitative research included in the Market Dynamix â„¢: NAFLD / NASH (United States) The service thoroughly assesses the etiology of the disease, diagnostic and therapeutic trends, as well as responses to potential therapies in development.

The need for pipeline therapies to gain FDA approval and fill the gap in the market is evident as the majority of physicians agree that there is a significant unmet need for treatment options in NAFLD / NASH. . In a separate question regarding the challenges of managing these diseases, “lack of effective therapy” was mentioned more than any other challenge by the physicians surveyed.

According to gastroenterologists and hepatologists, the most important attribute of NAFLD / NASH pipeline therapies is effectiveness in improving and preventing fibrosis. Qualitatively, doctors added that this reflects the urgent need to treat patients who are approaching the stage of cirrhosis as a result of NASH. Another key attribute of the pipeline is efficacy in reducing hepatic fat, which sparked significant discussions about which patients needed this treatment feature and whether combination therapy was the answer.

Along with assessing potential factors for developing agents, the Spherix report included in this new service assesses physicians’ knowledge and familiarity with ten pipeline assets that have at least Phase 2 clinical data available. These pipeline therapies include:

  • Aldafermine (NGMBio)
  • Aramchol (Galmed Pharmaceuticals)
  • Efruxifermin (Akero Therapeutics)
  • Lanifibranor (Inventiva)
  • Namodenoson (Can-Fite BioPharma)
  • Pegbelfermin / BMS-986036 (BMS)
  • Resmetirom / MGL-3196 (Madrigal Pharmaceuticals)
  • Semaglutide (Novo Nordisk)
  • Tropifexor (Novartis)
  • VK2809 (Viking Therapeutics)

Doctors’ current familiarity with pipeline therapies is generally low, as qualitative respondents clarified that they will invest more time to level up when clear winners emerge from the clinical trial process. Gastroenterologists and hepatologists conducted a thorough review of these pipeline product descriptions (based on publicly available clinical information for each product). The quantitative data captured for these NAFLD / NASH pipeline therapies include:

  • More likely to prescribe NAFLD / NASH treatment (probability estimate if FDA approved)
  • Most Preferred NAFLD / NASH Pipeline Therapy (Ranking)
  • Reasons to rank therapy number one
  • Number of patients who would start each therapy ranked number one
  • Severity / stages of patient candidates for pipeline therapies
  • Physicians’ patient “storage” level for therapies that may be approved by the FDA
  • Knowledge of combination therapies for NAFLD / NASH
  • Combination Therapies for NAFLD / NASH Doctors Would Like to See
  • Preference for combination therapies over monotherapies for NAFLD / NASH

The quantitative and qualitative data included in Spherix Market Dynamix â„¢: NAFLD / NASH (United States) report indicate that the desire for an FDA-approved therapy is evident to gastroenterologists and hepatologists. It should be noted that manufacturers seem to be aware of this unmet need, as the pipeline is currently quite crowded. As these manufacturers attempt to navigate the pipeline, this report provides information and advice on the current market as well as the opinions and desires of physicians for the future.

NAFLD / NASH represents just one of the emerging gastroenterological conditions introduced in Spherix’s gastroenterological offerings via the Market Dynamix â„¢ a service. Other conditions covered include eosinophilic esophagitis and celiac disease.

About Market Dynamix â„¢
Market Dynamix â„¢ is an independent service providing analysis of markets expected to experience a paradigm shift in the next three to five years. The information highlights market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents. Learn more about our services here.

About Spherix Global Insights
Spherix Global Insights is a hyper-focused business intelligence company that leverages our own independent data and expertise to provide strategic advice, so biopharmaceutical stakeholders make confident decisions. We specialize in certain markets of immunology, nephrology and neurology.

All company, brand, or product names in this document are trademarks of their respective holders.

For more information contact:
Kristen henn, Responsible for business development
E-mail: [email protected]

SOURCE Spherix Global Insights

Related links


About Rhonda Lee

Check Also

Mycobacterium abscessus pneumonia in severe alcoholism

In the USA, Mycobacterial tuberculosis the infection is not common and the infection rate has …

Leave a Reply

Your email address will not be published.